Tropifexor safe up to 48 weeks for NASH

New data showed favorable safety measures up to 48 weeks of treatment with tropifexor in nonalcoholic steatohepatitis, according to a presenter at The Liver Meeting Digital Experience.“The role of tropifexor as part of a combination therapy indicated for the treatment of fibrotic NASH is also being investigated in ongoing studies,” Arun J. Sanyal, MD, from the Diabetes and Endocrinology Consultant in Morehead City, North Carolina, said during his presentation.Sanyal presented results from part C of the phase 2 FLIGHT-FXR study.The investigators randomly assigned 152 patients withRead More

Share on facebook
Share on twitter
Share on linkedin